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Abstract

Key Points

IMPORTANCE Emerging evidence supports the use of outpatient parenteral antimicrobial therapy
(OPAT) and, in many cases, partial oral antibiotic therapy for the treatment of injection drug
use–associated infective endocarditis (IDU-IE); however, long-term outcomes and cost-effectiveness
remain unknown.

Question What is the most clinically
beneficial and cost-effective antibiotic
treatment strategy for injection drug
use–associated infective endocarditis
(IDU-IE)?

OBJECTIVE To compare the added value of inpatient addiction care services and the cost-

Findings In this decision analytical

effectiveness and clinical outcomes of alternative antibiotic treatment strategies for patients

modeling study simulating 4 treatment

with IDU-IE.

strategies among 5 million individuals
with IDU-IE in the US, a validated

DESIGN, SETTING, AND PARTICIPANTS This decision analytical modeling study used a validated

microsimulation model suggested that

microsimulation model to compare antibiotic treatment strategies for patients with IDU-IE. Model

outpatient parenteral antimicrobial

inputs were derived from clinical trials and observational cohort studies. The model included all

therapy was the most cost-effective

patients with injection opioid drug use (N = 5 million) in the US who were eligible to receive OPAT

strategy for the treatment of IDU-IE. A

either in the home or at a postacute care facility. Costs were annually discounted at 3%. Cost-

partial oral antibiotic treatment strategy

effectiveness was evaluated from a health care sector perspective over a lifetime starting in 2020.

was associated with the highest

Probabilistic sensitivity, scenario, and threshold analyses were performed to address uncertainty.

treatment completion rate and was
most cost-effective when methicillin-

INTERVENTIONS The model simulated 4 treatment strategies: (1) 4 to 6 weeks of inpatient

resistant Staphylococcus aureus was not

intravenous (IV) antibiotic therapy along with opioid detoxification (usual care strategy), (2) 4 to 6

a causative pathogen.

weeks of inpatient IV antibiotic therapy along with inpatient addiction care services that offered
medication for opioid use disorder (usual care/addiction care strategy), (3) 3 weeks of inpatient IV
antibiotic therapy along with addiction care services followed by OPAT (OPAT strategy), and (4) 3
weeks of inpatient IV antibiotic therapy along with addiction care services followed by partial oral
antibiotic therapy (partial oral antibiotic strategy).

Meaning This study found that
outpatient parenteral antimicrobial
therapy and partial oral antibiotic
therapy regimens were likely to be as
clinically beneficial as and less costly
than 6 weeks of inpatient intravenous

MAIN OUTCOMES AND MEASURES Mean percentage of patients completing treatment for IDU-IE,
deaths associated with IDU-IE, life expectancy (measured in life-years [LYs]), mean cost per person,

antibiotic therapy for the treatment
of IDU-IE.

and incremental cost-effectiveness ratios (ICERs).
RESULTS All modeled scenarios were initialized with 5 million individuals (mean age, 42 years;
range, 18-64 years; 70% male) who had a history of injection opioid drug use. The usual care strategy
resulted in 18.63 LYs at a cost of $416 570 per person, with 77.6% of hospitalized patients completing

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

treatment. Life expectancy was extended by each alternative strategy. The partial oral antibiotic
strategy yielded the highest treatment completion rate (80.3%) compared with the OPAT strategy
(78.8%) and the usual care/addiction care strategy (77.6%). The OPAT strategy was the least
expensive at $412 150 per person. Compared with the OPAT strategy, the partial oral antibiotic
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Abstract (continued)

strategy had an ICER of $163 370 per LY. Increasing IDU-IE treatment uptake and decreasing
treatment discontinuation made the partial oral antibiotic strategy more cost-effective compared
with the OPAT strategy. When assuming that all patients with IDU-IE were eligible to receive partial
oral antibiotic therapy, the strategy was cost-saving and resulted in 0.0247 additional discounted
LYs. When treatment discontinuation was decreased from 3.30% to 2.65% per week, the partial oral
antibiotic strategy was cost-effective compared with OPAT at the $100 000 per LY threshold.
CONCLUSIONS AND RELEVANCE In this decision analytical modeling study, incorporation of OPAT
or partial oral antibiotic approaches along with addiction care services for the treatment of patients
with IDU-IE was associated with increases in the number of people completing treatment, decreases
in mortality, and savings in cost compared with the usual care strategy of providing inpatient IV
antibiotic therapy alone.
JAMA Network Open. 2022;5(2):e220541. doi:10.1001/jamanetworkopen.2022.0541

Introduction
Hospitalizations associated with infective endocarditis in the US increased from 16 per 100 000
adults in 2003 to 22 per 100 000 adults in 2016.1 Injection drug use–associated infective
endocarditis (IDU-IE) currently accounts for 1 in 10 hospitalizations for infective endocarditis.2 This
increase has largely been associated with the opioid epidemic, specifically the injection of heroin and
fentanyl. If current patterns continue, more than 250 000 individuals in the US may die of IDU-IE
between 2020 and 2030.3 There is a substantial need to define optimal treatment strategies given
the increasing burden of IDU-IE in the US.
Standard treatment for IDU-IE comprises 4 to 6 weeks of intravenous (IV) antibiotic therapy.4
Emerging evidence exists for the use of oral antibiotic therapy for the treatment of many types of
infective endocarditis and the use of outpatient parenteral antimicrobial therapy (OPAT) for at least
part of the treatment course.5-9 However, patients with IDU-IE are often required to remain
hospitalized until treatment completion.10 Almost 20% of patients admitted with IDU-IE have a
patient-directed discharge (ie, leave the hospital against medical advice).11,12 Alternative antibiotic
treatment strategies that shorten hospitalization and allow patients to complete treatment
elsewhere could increase the likelihood of treatment completion and decrease costs.
Current US treatment guidelines state that partial oral antibiotic therapy may be a reasonable
option for patients with IDU-IE associated with uncomplicated right-sided Staphylococcus aureus
infection but recommend that this approach only be used when parenteral antibiotic therapy is
problematic.13,14 However, a retrospective cohort study5 found that people with IDU-IE who received
a complete course of IV antibiotic therapy had similar readmission rates to those who could not
complete inpatient IV antibiotic therapy and were provided partial oral antibiotic therapy at the time
of patient-directed discharge.
Another strategy, OPAT, is widely used to treat infections that require prolonged antibiotic
therapy, and this treatment strategy has a proven safety record.15 However, clinicians’ concerns
regarding the misuse of a peripherally inserted central catheter to inject drugs in addition to
treatment nonadherence, unstable living situations, and stigma associated with substance use have
typically excluded people who inject drugs from receiving OPAT.16,17 Despite these concerns, a 2018
systematic review8 found that OPAT may be safe and beneficial for treating IDU-IE. To our
knowledge, no study to date has compared the long-term impact and cost-effectiveness of OPAT
with IV and partial oral antibiotic treatment strategies.
Recent research18 has highlighted the role of addiction care services in improving outcomes
among individuals hospitalized with IDU-IE. Addiction care services, which can include addiction
counseling, opioid withdrawal management, long-term medication titration, and referral and linkage
JAMA Network Open. 2022;5(2):e220541. doi:10.1001/jamanetworkopen.2022.0541 (Reprinted)
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to outpatient addiction care, have been reported to increase the likelihood of receiving medication
for opioid use disorder (MOUD) during and after treatment for IDU-IE and have been associated with
reductions in mortality risk19 and decreases in the probability of reinfection.20,21 Despite these
benefits, an analysis from 1 hospital found that fewer than 8% of patients admitted with IDU-IE were
discharged with any plans to start MOUD,22 reflective of a gap in treatment which has since been
confirmed in broader studies.19,20
We evaluated the likely long-term clinical outcomes and cost-effectiveness of different
strategies for the treatment of IDU-IE. Given the emerging evidence and unanswered questions, we
aimed to (1) compare the potential value of alternative antibiotic treatment strategies and (2)
estimate the impact of addiction care services among patients with IDU-IE.

Methods
The study was approved by the Boston University Medical Campus Institutional Review Board, which
reviewed the Reducing Infection Related to Drug Use Cost-Effectiveness (REDUCE) model used in
the study and provided a waiver of informed consent because the study did not involve human
participants. This study followed the Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) reporting guideline for economic evaluations of health interventions (eMethods 1 in the
Supplement).23

Analytic Overview
We used the REDUCE model, a validated Monte Carlo microsimulation model that simulated the
natural history of injection opioid use, to compare the following treatment strategies for IDU-IE: (1) 4
to 6 weeks of inpatient IV antibiotic therapy along with opioid detoxification (usual care strategy),
(2) 4 to 6 weeks of inpatient IV antibiotic therapy along with inpatient addiction care services that
offered MOUD (usual care/addiction care strategy), (3) 3 weeks of inpatient IV antibiotic therapy
along with addiction care services followed by OPAT (OPAT strategy), and 4) 3 weeks of IV antibiotic
therapy along with addiction care services followed by partial oral antibiotic therapy (partial oral
antibiotic strategy).
In 3 of the strategies (usual care/addiction care, OPAT, and partial oral antibiotic therapy),
patients with IDU-IE could receive addiction care services while hospitalized. These strategies were
based on the assumption that when addiction care services were implemented, hospitalized
individuals would have an increased probability of receiving MOUD in addition to addiction
counseling, opioid withdrawal management, long-term medication titration, and referral and linkage
to outpatient addiction care at the end of hospitalization.
In the OPAT strategy, all hospitalized patients with IDU-IE transitioned to either home-based or
outpatient OPAT after 3 weeks of hospitalization and the offer of addiction care services. We
assumed that 50% of patients would have home infusion therapy and 50% would receive OPAT at a
postacute care facility. This assumption was informed by unpublished data from Boston Medical
Center (A. Hill, BA, email communication, June 3, 2021) suggesting that one-half of patients with
IDU-IE were homeless and therefore could not be discharged home. For the partial oral antibiotic
strategy, we assumed that only patients admitted with non–methicillin-resistant S aureus
(non-MRSA) IDU-IE would be eligible to receive oral antibiotic therapy after 3 weeks of
hospitalization; however, all patients would be eligible to receive addiction care services. The
probability of treatment completion and costs differed for each strategy. Details of these parameters
and parameter sources are available in eMethods 1 in the Supplement.
The REDUCE model simulated a closed cohort of people who injected short-acting opioid drugs.
For this analysis, we simulated a cohort over a lifetime to estimate long-term outcomes, including
the mean percentage of patients completing treatment for IDU-IE, deaths associated with IDU-IE, life
expectancy (measured in life-years [LYs]), mean cost per person, and incremental costeffectiveness ratios (ICERs). We compared costs using a payer system perspective and denominated
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currency in 2020 US dollars. We discounted all costs and benefits by 3% annually and expressed
ICERs as cost per LY gained, with a willingness-to-pay threshold of $100 000 per LY.24 We evaluated
LYs rather than quality-adjusted LYs because the interventions focused on mortality-based
outcomes, and quality-adjusted LYs are intended to measure life expectancy among patients with
diseases in which there is a measurable change in quality of life (eg, heart failure) and the experience
with drug use is heterogeneous. Probabilistic sensitivity, scenario, and threshold analyses were
performed to evaluate major findings.

REDUCE Model Overview
Model Structure and Simulated Cohort
The REDUCE model has been described in detail elsewhere.3 The model simulated a closed cohort
experiencing the natural history of injection opioid drug use. Individuals moved through time in
weekly steps from model initialization until death. Each week, there was a probability of developing
sequelae of injection opioid drug use (eg, overdose or IDU-IE), requiring hospitalization, receiving
outpatient addiction care, and changing injection drug use behavior.
The simulated cohort was stratified by sex (male or female), age (0-99 years), and injection
behavior profile, which included injection frequency (high, low, or not currently injecting drugs),
sharing of injection equipment (yes, no, or never), and sterile injection technique (cleaning, no
cleaning, or never) (eMethods 1 and eTable 1 in the Supplement).
Sequelae of Drug Use
We assumed that individuals with high-frequency injection drug use had a higher probability of both
overdose and IDU-IE, and individuals who shared injection equipment or used unsterile injection
techniques had a higher probability of IDU-IE (eMethods 1, eTable 2, and eTable 3 in the Supplement).
Overdose and infection risks were stratified by age and sex.
Hospitalization
We assumed that after developing IDU-IE or experiencing an overdose, individuals had a probability
of hospitalization. While hospitalized, patients could receive MOUD and a consultation for addiction
care services, if available. We also assumed that individuals receiving MOUD and addiction care
services had a higher probability of linking to outpatient MOUD and addiction care, and both
outcomes changed the probability of decreasing the frequency of injection drug use (eMethods 2
and eTable 4 in the Supplement). Not all patients receiving addiction care services began receiving
MOUD. While hospitalized, patients had a probability of leaving before treatment completion. We
assumed that patients who did not complete treatment for IDU-IE would remain infected until they
were readmitted to the hospital or died.
Outpatient Treatment Services
We assumed that when individuals left the hospital, they had a probability of linking to outpatient
addiction care services and MOUD (eMethods 2 and eTable 5 in the Supplement). Linkage could be
increased through receipt of inpatient addiction care services and MOUD but could also occur
spontaneously through a background mechanism reflecting outpatient addiction care uptake in the
nonhospitalized population.
The OPAT and partial oral antibiotic strategies simulated the provision of outpatient antibiotic
therapy to individuals with IDU-IE (eMethods 3 and eTables 6-12 in the Supplement). We
incorporated a weekly probability of discontinuing treatment for IDU-IE.
Mortality
We assumed that individuals had a probability of dying of overdose and IDU-IE in addition to age-,
sex-, and drug use–adjusted mortality from competing causes of death (eMethods 2 in the
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Supplement). At hospitalization, individuals had an additional mortality risk applied to reflect
inpatient mortality.
Costs
Each patient accrued costs associated with opioid use, hospitalization, and outpatient services. Care
costs associated with opioid use varied by injection behavior profile. The cost analysis also accounted
for health care services, stratified by age and sex, that were not associated with opioid use based on
data from the Medical Expenditure Panel Survey.25

Model Data and Parameter Estimation
Population, sequelae of drug use, inpatient, outpatient, mortality, and cost parameters were included
in the model. The parameters and data sources are summarized in Table 1,4-8,11,25-64 and full details
are available in eTable 1 to eTable 12 in the Supplement.
Overdose and Hospitalization
We derived rates of fatal and nonfatal overdose from state-level data.36-38 Rates of IDU-IE were
derived from the published literature.4,65-67
Data from the published literature and expert opinion (H. Englander, MD, and C. King, PhD,
email communication, October 20, 2019) informed the rates of hospitalization, the probability of
initiating MOUD while an inpatient, and the association of addiction care services and MOUD with
injection frequency. We assumed that 26% of individuals accepted addiction care services while
inpatients based on unpublished data from Boston Medical Center addiction care services (Z.M.
Weinstein, MD, email communication, March 12, 2019).
Outpatient Treatment Services
We assumed that individuals receiving inpatient addiction care services and MOUD had a 70%
probability of linking to outpatient MOUD compared with individuals receiving inpatient MOUD
alone (45% linkage), individuals receiving addiction care services alone (57% linkage), and individuals
not receiving either inpatient MOUD or addiction care services (5% linkage). We estimated the
conditional probabilities of linking to outpatient MOUD based on data from cohort studies and
clinical trials.48,49 The probabilities of completing OPAT and partial oral antibiotic therapies were
informed by data from the published literature.5-8
Mortality and Costs
After accounting for fatal overdose, we derived age- and sex-adjusted mortality rates from the
National Vital Statistics System to inform mortality associated with competing risks.54,55 To account
for additional opioid drug use–associated harms not captured by fatal overdose or IDU-IE, we
multiplied the resulting mortality rates by 1.2.54
We derived some of the costs from the 2020 Laboratory and Physician Fee Schedules from the
Centers for Medicare and Medicaid Services63,64 and the Medical Expenditure Panel Survey25
(eTable 10 and eTable 11 in the Supplement).
Probabilistic, Scenario, and Threshold Analyses
For the main analysis, we performed probabilistic sensitivity analyses (eMethods 4 in the
Supplement) using distributions around important model parameters. We performed 1000
simulations with 5 million individuals over a lifetime.
Deterministic sensitivity analyses were conducted to evaluate the extent of uncertainty in the
input parameters (eMethods 4 in the Supplement). These analyses were performed with 500 000
individuals over a lifetime. We varied (1) the percentage of patients with IDU-IE who were eligible to
receive partial oral antibiotic therapy (to reflect differences in the percentage of non-MRSA IDU-IE
cases), (2) the percentage of patients leaving the hospital with patient-directed discharge, (3) the
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Table 1. Estimates for Important Model Parameters to Characterize Outcomes of People Who Inject Drugs
Over a Lifetime
Parametera
Population

Estimate

Range

Source

Probability of ever drug use

100% of cohort ever
injected drugs; age
and sex mix informed
by literature
Varied by age and sex

NA

NA

Lansky et al,26 2014; Martins
et al,27 2017; Degenhardt
et al,28 2017; CDC,29 2021; US
Census Bureau,30 2018
Tan et al,31 2018; Buresh
et al,32 2019

Low-frequency injection drug use

0.0026

0.0026-0.0027

High-frequency injection drug use

0.0005

0.0005-0.0006

Probability of fatal overdose

0.1300

0.1200-0.2400

Proportion of IDU-IE infections

100

NA

CDC,29 2021; Hser et al,33
2017; Hudgins et al,34 1995;
Cedarbaum & Banta-Green,35
2016; MDPH,36 2017; MDPH,37
2020; Hedegaard et al,38 2018
MDPH,36 2017; MDPH,37 2020;
Hedegaard et al,38 2018
Assumed

Probability of linking to inpatient care
after nonfatal overdose
Probability of linking to inpatient care
for IDU-IE
Probability of linking to inpatient care
for SSTI
Previous overdose multiplier for risk of
subsequent overdose, No. of nonfatal
overdoses
1

0.9700

NA

Expert opinionb

0.2000

0.1830-0.2170

N’Guyen et al,39 2017

0.0019

0.0008-0.0040

Hope et al,40 2015

Probability of injection drug use
frequency
Sequelae of drug use
Probability of overdose

1.15

0.72-1.82

2-3

1.81

1.19-2.27

4-7

2.12

1.11-4.04

≥8

Caudarella et al,41 2016

5.24

1.56-17.01

Previous infection multiplier for risk of
subsequent infection
Inpatient

2.80

1.50-5.10

Alagna et al,42 2014

Duration of hospitalization with IDU-IE
using usual care scenarios, mean, wk
Probability of patient-directed discharge

6

4-8

Miller and Polgreen,4 2019

0.0500

0.0300-0.1000

Probability of addiction consultation
service uptake, if available
Probability of initiation of MOUD with an
addiction consultation
Probability of initiation of MOUD without
an addiction consultation
Probability of initiation of OPAT

0.2580

0.0400-0.4000

Kimmel et al,11 2021; Meisner
et al,43 2020
Unpublished BMC addiction care
data; expert communicationc

0.6500

0.3200-0.9700

0.1100

0.0500-0.1600

Unpublished ALIVE data; Priest
et al,44 2020; Murphy et al,45
2019; Englander et al,46 2020d

0.5360

0.159-0.587

Expert opinion

Probability of initiation of POA therapy

0.2290

0.159-0.3188

Rodger et al,47 2018

3

2-4

Fanucchi et al,6 2020

Outpatient
Antibiotic treatment
Duration of OPAT, wk
Duration of POA therapy, wk

3

2-4

Marks et al,5 2020

Probability of discontinuing OPAT

0.0454

0.0300-0.1400

0.0330

0.0200-0.1100

Fanucchi et al,6 2020; D’Couto
et al,7 2018; Suzuki et al,8
2018
Marks et al,5 2020

0.7000

0.6700-0.7220

0.5714

0.5404-0.6024

Unpublished data; Liebschutz
et al,48 2014; Trowbridge
et al,49 2017e
Unpublished datae

0.4529

0.4415-0.4643

Unpublished datae

0.0500

0.0490-0.0501

Knudsen et al,50 2011;
Larochelle et al,51 2018

Probability of discontinuing POA
therapy
Addiction care and MOUD linkage
Link to outpatient addiction care with
MOUD after inpatient addiction care
with MOUD
Link to outpatient addiction care with
MOUD after inpatient MOUD without
addiction care
Link to outpatient addiction care
without MOUD after inpatient
addiction care without MOUD
Link to outpatient addiction care
without MOUD after inpatient MOUD
without addiction care

(continued)
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Table 1. Estimates for Important Model Parameters to Characterize Outcomes of People Who Inject Drugs
Over a Lifetime (continued)
Parametera
MOUD initiation

Estimate

Range

Source

Link to outpatient addiction care after
inpatient addiction care
Link to outpatient addiction care after
no inpatient addiction care
Unlinkage

0.5069

0.4649-0.5489

Unpublished datae

0.1620

0.1439-0.3430

Knudsen et al,50 2011

Spontaneous unlinking from outpatient 0.0481
addiction care and MOUD
Spontaneous unlinking from outpatient 0.1560
addiction care and no MOUD
Mortality

0.0298-0.0666

Liebschutz et al,48 2014;
Morgan et al,52 2018
Liebschutz et al,48 2014;
Wakeman et al,53 2017

Background overdose–subtracted
mortality
Probability of death

Varied by age and sex

0.0008-0.0011

Chang et al,54 2017; Arias,55
2012

Untreated IDU-IE

0.1623

0.0848-0.5358

Untreated SSTI

0.0023

0.0023-0.0028

Inpatient with IDU-IE

0.0100

0.0018-0.0161

Inpatient with SSTI

0.0008

0.0008-0.0025

Inpatient with overdose

0.0190

0.0130-0.0270

Verhagen et al,56 2006;
Veldhuizen and Callaghan,57
2014
Veldhuizen and Callaghan,57
2014
Veldhuizen and Callaghan,57
2014; Rodger et al,47 2018;
Cresti et al,58 2017; Hill et al,59
2007; Ternhag et al,60 2013
Veldhuizen and Callaghan,57
2014
Jiang et al,61 2017

Varied by age and sex

NA

AHRQ,25 2021

No current use

224

112-336

Murphy et al,45 2019

High

357

178-536

Behrends et al,62 2019

Low

238

119-357

Murphy et al,45 2019

Fatal

430

215-645

Behrends et al,62 2019

Nonfatal without hospitalization

1118

559-1678

Behrends et al,62 2019

With IDU-IE

21 573

8736-34 410

Miller and Polgreen,4 2019

With SSTI

17 751

9124-26 378

Miller and Polgreen,4 2019

With overdose

14 195

12 744-15 646

Behrends et al,62 2019

Addiction care services

225

150-300

POA medications and services

380

137-1289

Unpublished BMC addiction care
data; CMS,63 2020f
CMS,63 2020; CMS,64 2020

OPAT at postacute care facility

2702

762-11 756

Unpublished BMC datag

Home-based OPAT medications and
services
Addiction consultation with MOUD

469

461-479

CMS,63 2020; CMS,64 2020

81

78-138

CMS,63 2020; CMS,64 2020

Addiction consultation without MOUD

81

62-138

Murphy et al,45 2019; CMS,63
2020; CMS,64 2020

0.1262-0.1860

Costs, $
Background costs
Frequency of injection drug use

Overdose

Hospitalization

Outpatient

Abbreviations: AHRQ, Agency for Healthcare Research and Quality; ALIVE, AIDS Linked to the Intravenous Experience
study; BMC, Boston Medical Center; CDC, Centers for Disease Control and Prevention; CMS, Centers for Medicare &
Medicaid Services; IDU-IE, injection drug use–associated infective endocarditis; MDPH, Massachusetts Department of
Health; MOUD, medication for opioid use disorder; NA, not applicable; OPAT, outpatient parenteral antibiotic therapy;
POA, partial oral antibiotic; SSTI, skin and soft tissue infection.
a

The REDUCE model was performed using a weekly time cycle; therefore, all probabilities are weekly.

b

Consensus obtained between B.P.L. and J.A.B.

c

Expert communication with H. Englander, MD, and C. King, PhD, via email on October 20, 2019.

d

Unpublished ALIVE data provided by G. Kirk, MD, and S. Mehta, MD, via email communication on March 7, 2019.

e

Unpublished data provided by K. Priest, MD, via email communication on October 20, 2019.

f

Unpublished BMC data provided by Z.M. Weinstein, MD, via email communication on March 12, 2019.

g

Unpublished BMC data provided by A. Hill, BA, via email communication on June 3, 2021.
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treatment uptake of OPAT and partial oral antibiotic therapy, (4) the rate of overdose within the
community and outpatient settings, (5) the uptake of addiction care services and MOUD during
hospitalization, and (6) the length of inpatient stay and uptake of partial oral antibiotic therapy. We
also conducted threshold analyses to assess which values for selected parameters (eg, treatment
uptake or treatment completion) changed our major findings (eMethods 4, eTable 13 in the
Supplement).

Statistical Analysis
The model was constructed using C++ programming language, and analyses were performed using R
software, version 3.2.2 (R Foundation for Statistical Computing), and Excel software (Microsoft
Corporation). No significance tests were performed for this simulation study.

Results
We initialized the model with a cohort of 5 million individuals who reflected the age and sex of the US
population who inject opioid drugs, with data informed by the US Census and published
literature.26-28,30-32,68 At model initialization, the mean age of the cohort was 42 years (range, 18-64
years), 70% were male, 53% had high-frequency injection drug use, 11% had low-frequency injection
drug use, and 36% had no current injection drug use.26-28,30-32,68 We assumed imperfect access to
harm reduction services, with 66% of the cohort practicing unsterile injection techniques and 45%
sharing injection equipment.69
Over a lifetime horizon within the usual care strategy, 685 637 individuals developed IDU-IE,
557 386 were hospitalized with IDU-IE, and 250 654 died of IDU-IE. The usual care strategy resulted
in 18.63 LYs; 77.6% of hospitalized patients with IDU-IE completed treatment, and 5.01% of deaths
in the population attributable to IDU-IE (Table 2). Life expectancy was extended by each alternative
strategy (0.016 years with the usual care/addiction care strategy, 0.013 years with the OPAT strategy,
and 0.024 years with the partial oral antibiotic strategy). The partial oral antibiotic strategy provided
the highest treatment completion rate (80.3%) compared with the OPAT strategy (78.8%) and the
usual care/addiction care strategy (77.6%). All strategies were attributable to a lower percentage of
IDU-IE–associated deaths compared with the usual care strategy (4.86% with the usual care/
addiction care strategy, 4.89% with the OPAT strategy, and 4.79% with the partial oral antibiotic
strategy vs 5.01% with the usual care strategy) and overdose (15.70% with the usual care/addiction

Table 2. Selected Cost and Clinical Outcomes from Base Case Analysisa
IDU-IE
completed
treatments,
No. (%)

Deaths
associated with
IDU-IE, No. (%)

685 637

432 720
(77.6)

OPAT

684 867

POA

Incremental
discounted
cost, mean, $

Discounted LY,
mean
Incremental
Hospital
discounted LY
cost, mean, $ (95% CrI)

ICER, $ per LYc

416 570
(334 000-482 780)

NA

13 968

18.63
NA
(17.28-18.67)

NA

73.34

412 150
(331 540-481 460)

4385

5450

18.65
0.0132
(17.32-18.70)

Cost-saving

239 507
(4.79)

73.37

413 920
(333 220-483 000)

1740

8520

18.66
0.0106
(17.34-18.74)

163 370

243 176
(4.86)

73.35

416 990
(334 580-483 530)

3098

14 162

18.65
Dominatedd
(17.30-18.70)

Dominatedd

Life
expectancy, y

Discounted cost,
mean (95% CrI), $

250 654
(5.01)

73.31

437 547
(78.8)

244 658
(4.89)

686 219

444 159
(80.3)

Usual care/ 684 036
addiction
care

438 588
(77.6)

Treatment
strategyb

IDU-IE
cases, No.

Usual care

care services that offered MOUD. The OPAT strategy comprised 3 weeks of inpatient IV
antibiotic therapy along with addiction care services followed by OPAT. The POA
strategy comprised 3 weeks of inpatient IV antibiotic therapy along with addiction care
services followed by POA therapy.

Abbreviations: CrI, credible interval; ICER, incremental cost-effectiveness ratio; IDU-IE,
injection drug use–associated infective endocarditis; LY, life-year; NA, not applicable;
OPAT, outpatient parenteral antimicrobial therapy; POA, partial oral antibiotic.
a

b

Analysis assumed that 21% of IDU-IE cases were associated with methicillin-resistant
Staphylococcus aureus and ineligible for POA therapy; 95% CrIs were calculated, if
applicable.
The usual care strategy comprised 4 to 6 weeks of inpatient intravenous (IV) antibiotic
therapy along with opioid detoxification. The usual care/addiction care strategy
comprised 4 to 6 weeks of inpatient IV antibiotic therapy along with inpatient addiction

c

The overall incremental cost-effectiveness ratio was calculated as the difference in the
mean discounted costs for the total US population divided the difference in the
discounted quality-adjusted life expectancy for the total US population, all of which
were discounted at 3% per year.

d

Cost more and had worse clinical outcomes.
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care strategy, 15.71% with the OPAT strategy, and 15.71% with the partial oral antibiotic strategy vs
15.73% with the usual care strategy).
The usual care strategy yielded a discounted lifetime mean cost of $416 570 per person (95%
credible interval [CrI], $334 000-$482 780) whereas the OPAT strategy was the least expensive at
$412 150 per person (95% CrI, $331 540-481 460) compared with the partial oral antibiotic strategy
($413 920 per person; 95% CrI, $333 220-$483 000) and the usual care/addiction care strategy
($416 990 per person; 95% CrI, $334 580-483 530). The usual care strategy was dominated by (ie,
cost more and had worse clinical outcomes) all other strategies. Compared with the OPAT strategy,
the partial oral antibiotic strategy had an ICER of $163 370 per LY. The usual care/addiction care
strategy was dominated by the partial oral antibiotic strategy.
In the scenario analyses, the partial oral antibiotic strategy was preferred (ie, performed best)
when patients with MRSA-associated IDU-IE were assumed to be eligible to receive partial oral
antibiotic therapy, when treatment uptake of partial oral antibiotic therapy or OPAT was held equal,
and when the inpatient stay was decreased and treatment uptake of partial oral antibiotic therapy
was increased (Table 3). Incremental discounted LYs gained with the partial oral antibiotic strategy
ranged from 0.020 (treatment uptake equal to OPAT treatment uptake) to 0.025 (MRSA-associated
IDU-IE eligible for treatment), and incremental discounted costs ranged from −$4450 to −$1250. In
a scenario analysis that assumed addiction care services reduced patient-directed discharge from
5.0% to 2.5% per week, the OPAT strategy was the most cost-effective, with a gain of 0.250 LYs and
incremental mean discounted cost of −$4073. Increasing the uptake of addiction care services and
MOUD from 25% to 75% yielded greater cost for each strategy but similar conclusions (mean
discounted costs increased from $412 150 to $412 420 for the partial oral antibiotic strategy and from
$413 920 to $414 300 for the OPAT strategy).
Clinicians have expressed concern regarding the possibility of overdose while receiving
outpatient antibiotic therapy. In a scenario quadrupling the rate of overdose in the community, our
findings regarding improved outcomes with partial oral antibiotic and OPAT regimens did not
qualitatively change. The OPAT strategy was the least expensive at $312 670 per person compared
with the partial oral antibiotic strategy ($313 930 per person) and the usual care/addiction care
strategy ($316 250 per person) and resulted in 0.059 additional LYs. The partial oral antibiotic
strategy had an ICER of $167 410.
We performed several threshold analyses. First, because uncertainty remained regarding the
comparative benefit of IV vs partial oral antibiotic therapies, we performed a threshold analysis of the
minimum benefit of both partial oral antibiotic and OPAT strategies, lower than which the usual care
strategy provided the best outcomes (Figure 1; eFigures 1 and 2 in the Supplement). We found that
the usual care strategy provided the best outcome when treatment completion was lowered from
the base case of 87% to 83% for the OPAT strategy and from the base case of 90% to 80% for the
partial oral antibiotic strategy. When treatment completion was lowered to 83% for the OPAT
strategy and 80% for the partial oral antibiotic strategy, there was no longer a gain in LYs compared
with the usual care strategy. When completion of partial oral antibiotic therapy increased to 92%, the
partial oral antibiotic strategy was preferred to the OPAT strategy. Partial oral antibiotic therapy was
cost-effective compared with OPAT at the $100 000 per LY threshold.
Next, we explored the rate at which patients accepted a given therapy. When OPAT uptake
decreased from 100% to 79%, OPAT was no longer the preferred strategy because the mean
discounted cost of OPAT ($413 860) became equivalent in cost to the partial oral antibiotic treatment
strategy ($413 920). When partial oral antibiotic therapy uptake increased from 79% to 86%, partial
oral antibiotic therapy was the preferred strategy, with an ICER of $72 182 per LY (eFigure 1 in the
Supplement). In a threshold analysis assessing cost, when OPAT cost was $26 000 per week
(compared with $1590 per week in the base case model), the OPAT strategy no longer met the
$100 000 per LY willingness-to-pay threshold compared with the usual care strategy (eFigure 2 in
the Supplement).
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Table 3. Selected Cost and Clinical Outcomes from Scenario Analyses
IDU-IE
completed
treatments, %

Deaths
associated with
IDU-IE, %

Life
expectancy, y

Discounted
cost, mean, $

Incremental
discounted
cost, mean, $

Usual care

77.63

5.01

73.31

416 570

POA

82.03

4.77

73.37

412 120

OPAT

78.73

4.89

73.35

Usual care/
addiction care

77.58

4.86

Usual care

77.63

POA

86.58

OPAT
Usual care/
addiction care

Hospital cost,
mean, $

Incremental
Discounted LY discounted LY

ICER, $ per LYc

NA

13 968

18.63

NA

NA

4450

5360

18.66

0.0247

Cost-saving

412 150

34

5436

18.65

Dominatedd

Dominatedd

73.35

416 990

4840

14 162

18.65

Dominatedd

Dominatedd

5.01

73.31

416 570

NA

13 968

18.63

NA

NA

4.59

73.41

414 450

1950

8610

18.68

0.0190

102 880

82.21

4.78

73.37

412 500

4073

5516

18.66

0.0250

Cost-saving

87.99

4.54

73.42

417 780

3334

14 180

18.68

0.0047

716 448

Usual care

77.63

5.01

73.31

416 570

NA

13 968

18.63

NA

NA

POA

64.67

4.79

73.36

415 330

1240

10 960

18.66

0.0200

Cost-saving

OPAT

64.27

4.84

73.36

415 390

60

11 018

18.65

NA

Dominatedd

Usual care/
addiction care

77.58

4.86

73.35

416 990

1660

14 162

18.65

NA

Dominatedd

Usual care

63.33

3.21

63.37

315 000

NA

1337

14.22

NA

NA

POA

64.66

3.07

63.51

313 930

1250

972

14.29

0.0075

167 410

OPAT

63.53

3.14

63.50

312 670

2280

776

14.28

0.0593

Cost-saving

Usual care/
addiction care

64.37

3.11

63.49

316 250

2320

1343

14.28

Dominatedd

Dominatedd

Usual care

77.63

5.01

73.31

416 570

NA

13 968

18.63

NA

NA

POA

80.28

4.68

73.41

414 300

1890

8580

18.66

0.0032

581 240

OPAT

78.67

4.82

73.37

412 420

4160

5470

18.65

0.0201

Cost-saving

Usual care/
addiction care

77.32

4.67

73.38

417 260

3000

14 260

18.66

0.0069

430 360

Usual care

77.63

5.01

73.31

416 570

NA

13 968

18.63

NA

NA

POA

81.49

4.78

73.37

412 117

4454

6372

18.66

0.0240

Cost-saving

OPAT

78.73

4.89

73.35

412 150

34

5436

18.65

Dominatedd

Dominatedd

Usual care/
addiction care

77.58

4.86

73.35

416 990

4840

14 162

18.65

Dominatedd

Dominatedd

Scenarioa,b
No MRSA

Addiction care
reduces patientdirected discharge

Treatment uptake of
POA and OPAT set at
50%

Quadrupled overdose
rate

Increased uptake of
addiction care and
MOUD while
inpatient

Shortened inpatient
stay and increased
eligibility for POA
therapy

comprised 4 to 6 weeks of inpatient IV antibiotic therapy along with inpatient addiction
care services that offered MOUD. The OPAT strategy comprised 3 weeks of inpatient
IV antibiotic therapy along with addiction care services followed by OPAT. The POA
strategy comprised 3 weeks of inpatient IV antibiotic therapy along with addiction care
services followed by POA therapy.

Abbreviations: IDU-IE, injection drug use–associated infective endocarditis; ICER,
incremental cost-effectiveness ratio; LY, life-year; MOUD, medication for opioid use
disorder; MRSA, methicillin-resistant Staphylococcus aureus; NA, not applicable; OPAT,
outpatient parenteral antimicrobial therapy; POA, partial oral antibiotic.
a

b

Scenarios assumed (1) all patients with IDU-IE were eligible to receive POA therapy, (2)
addiction care services reduced the percentage of patient-directed discharges (ie,
leaving the hospital against medical advice) from 5.0% to 2.5% per week, (3) the
uptake of POA therapy or OPAT was limited to 50% of all patients, (4) the rate of
overdose within the community and outpatient settings was quadrupled, (5) increased
uptake of inpatient addiction care services and MOUD, and (6) inpatient stay was
shortened to 2 weeks and eligibility to receive POA therapy was increased.

c

The overall incremental cost-effectiveness ratio was calculated as the difference in the
mean discounted costs for the total US population divided the difference in the
discounted quality-adjusted life expectancy for the total US population, all of which
were discounted at 3% per year.

d

Cost more and had worse clinical outcomes.

The usual care strategy comprised 4 to 6 weeks of inpatient intravenous (IV) antibiotic
therapy along with opioid detoxification. The usual care/addiction care strategy
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Our major findings did not qualitatively change in the probabilistic sensitivity analyses (Table 2),
in which the percentages of patient-directed discharge and treatment uptake were held constant
while almost all other parameters were varied (Table 1). Probabilistic sensitivity analyses were used
to calculate CrI s for discounted LYs for the usual care (18.63 LYs; 95% CrI, 17.28-18.67 LYs), OPAT
(18.75 LYs; 95% CrI, 17.32-18.70 LYs), partial oral antibiotic therapy (18.66 LYs; 95% CrI, 17.34-18.74
LYs), and usual care/addiction care (18.65 LYs; 95% CrI, 17.30-18.70 LYs) strategies. A costeffectiveness acceptability curve (Figure 2) using output from the probabilistic sensitivity analyses
revealed that either the partial oral antibiotic or OPAT strategy yielded the greatest net monetary
benefit 100% of the time. Up to a willingness-to-pay threshold of $60 000, the OPAT strategy was
preferred, and at a willingness-to-pay threshold higher than $60 000, the partial oral antibiotic
strategy was preferred.

Discussion
In this microsimulation modeling study, treatment of IDU-IE with partial oral antibiotic therapy or
OPAT was associated with similar or improved long-term clinical outcomes compared with usual care
while also being cost-effective. Within our base case model, we assumed that patients with IDU-IE
associated with MRSA infection were not eligible to receive partial oral antibiotic therapy and, as a
result, the OPAT strategy was found to be the most cost-effective. Without the exclusion of MRSA
infection, the partial oral antibiotic strategy was optimal.
Up to 1 in 4 patients with IDU-IE die within 1 year after hospital admission.70 Challenges
associated with long periods of hospitalization may be justified if hospital stays improve outcomes;
however, establishment of the inferiority of alternative approaches is necessary. An increasing body
of evidence suggests that OPAT and partial oral antibiotic strategies are feasible for the treatment
of IDU-IE in this population, producing similar or improved clinical outcomes.5,6 Informed by these
existing studies, we modeled the long-term outcomes associated with offering alternative antibiotic
strategies paired with addiction care services and found that both the OPAT and partial oral antibiotic
strategies were associated with improved outcomes compared with the usual care strategy. Our
results suggest that OPAT and partial oral antibiotic regimens may be as clinically beneficial and less

Figure 1. Threshold Values for Treatment Completion

Treatment discontinuation per week, %

16
14
12
10
8
6
4
2
0
UC
base case

UC plus ACS
base case

OPAT
base case

OPAT
threshold

POA
base case

POA
POA
threshold A threshold B

Treatment scenario

Results of 3 threshold analyses examining which value of treatment discontinuation per
week changed the major findings. Error bars for the base case scenarios present the
upper and lower ranges of the uniform distribution implemented within the probability
sensitivity analyses for the partial oral antibiotic (POA) therapy and outpatient parenteral
antimicrobial therapy (OPAT) strategies or the normal distribution and 1 SD range for the
usual care (UC) and UC plus addiction care services (ACS) strategies. The brown bar
indicating the OPAT threshold represents the threshold value (6.01% per week) for the

percentage of patients discontinuing OPAT per week at which there was no longer a gain
in life-years (LYs) compared with the UC base case. The orange bar indicating POA
threshold A represents the threshold value (2.65%) for the percentage of patients
discontinuing POA per week at which POA was cost-effective compared with OPAT at a
$100 000 per LY threshold. The orange bar indicating POA threshold B represents the
threshold value (7.30%) for the percentage of patients discontinuing POA per week at
which there was no longer a gain in LYs compared with the UC base case.
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costly than the usual care regimen, and these findings support expanding opportunities to research
and implement these options among patients with IDU-IE. Our findings also reinforce the importance
of addiction care services and contribute to increasing evidence suggesting the necessity of
addiction care services for the treatment of individuals with opioid use disorder.18
Concerns regarding the efficacy of oral antibiotic medications have hindered efforts to expand
the use of partial oral antibiotic therapy for the treatment of IDU-IE. Within our main analysis, we
assumed that patients with MRSA-associated IDU-IE were ineligible to receive partial oral antibiotic
therapy but that otherwise the modeled antibiotic therapies had similar treatment completion rates
if the treatment course was completed. Adherence to and completion of antibiotic treatment are
important parameters to consider when assessing potential administration of partial oral antibiotic
regimens to patients with IDU-IE. Previous studies on the implementation of care for hepatitis C viral
infection among individuals who inject drugs and are receiving MOUD have reported high rates of
adherence to antiviral treatment regimens that were similar to the rates of antiretroviral treatment
adherence among people with HIV infection who inject drugs.71,72 Our threshold analysis revealed
that when 80% or more of the patients receiving partial oral antibiotic therapy and 83% or more of
the patients receiving OPAT successfully completed treatment, these regimens would continue to
improve life expectancy compared with usual care. Although the intention of the usual care approach
is universal treatment completion, the reality of noncompletion of treatment is likely
underappreciated when weighing the risks and benefits of treatment strategies. Within the model,
potential differences in the benefits of regimens were overcome by large differences in treatment
completion. The model also assumed that a full 6 weeks of therapy was needed before treatment
completion and that a mean inpatient stay of 3 weeks was needed before initiation of partial oral
antibiotic or OPAT regimens. Therefore, our estimate was likely conservative.
Access to postacute care facilities for administration of OPAT may limit the ability of institutions
to offer this treatment regimen.10,22 Postacute care facilities often refuse to accept patients with
histories of active substance use despite the fact that these practices violate the Americans with
Disabilities Act.16 However, we found within a scenario analysis that even when individuals had a very
high probability of overdose after leaving the hospital, alternative antibiotic regimens were
associated with improvement in outcomes compared with the usual care regimen. This finding
suggests that the opportunity to complete treatment and link to MOUD through addiction care
services may prevent more overdose fatalities than an extended hospital stay. These results can be
used as an advocacy tool for agencies such as Medicaid to work with postacute care facilities to
improve access to OPAT.
We accounted for some socioeconomic challenges, such as homelessness, by assuming that
only one-half of patients could receive at-home OPAT. There are circumstances in which

Figure 2. Cost-effectiveness Acceptability Curve for Injection Drug Use–Associated Infective Endocarditis
Antibiotic Treatment Strategies
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net monetary benefit, %
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hospitalization may be preferable to the alternative (eg, no housing), but administration of OPAT
within in a postacute care facility rather than a hospital may be preferable to both approaches.
However, the high rate of adverse events associated with OPAT, including peripherally inserted
central catheter line infection and thrombosis, will need to be considered when discussing
alternative antibiotic therapy strategies.9 Clinicians may consider engaging in patient-centered
decision-making when offering these treatment strategies, with housing not used as the sole
determining factor when selecting an antibiotic treatment strategy.

Limitations
This study has several limitations. First, we relied on a single published study to inform parameters on
partial oral antibiotic treatment completion and regimen costs. However, a prospective cohort
study73 examining the efficacy of a partial oral antibiotic regimen for patients with early patientdirected discharge is currently being conducted, and model parameters are within the currently
observed range. Second, although important model parameters were informed by studies of the
target population, unmeasured confounders may have impacted the results of these studies. Despite
these limitations, our findings did not qualitatively change in sensitivity analyses and when varying
assumptions were used, which may enable clinicians and hospital staff to consider these findings
within their local context.

Conclusions
Results from this decision analytical modeling study suggest that, if implemented, the strategies
could save the health care system a substantial amount of money in lifetime hospitalization costs
alone for the estimated 750 000 individuals currently injecting drugs in the US.26 Those savings
could be shifted to programs that specifically address the opioid epidemic, such as initiatives to
improve access to MOUD, promote safer injection techniques, and provide multidisciplinary
outpatient support systems, including peer navigators and case managers, to decrease the future
incidence of IDU-IE and support patient retention in substance use disorder care programs.
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